A5107004123- Retinal Diseases and Treatments
- Retinal Imaging and Analysis
- Retinal and Optic Conditions
- Retinal Development and Disorders
- Glaucoma and retinal disorders
- Angiogenesis and VEGF in Cancer
- Ocular Diseases and Behçet’s Syndrome
- Cerebral Venous Sinus Thrombosis
- Cerebrovascular and Carotid Artery Diseases
- Ocular and Laser Science Research
- RNA regulation and disease
- Peripheral Artery Disease Management
- Cell Image Analysis Techniques
- Coronary Interventions and Diagnostics
- Connective tissue disorders research
- Ophthalmology and Eye Disorders
- Ocular Oncology and Treatments
- Acute Ischemic Stroke Management
- Retinal and Macular Surgery
- Optical Coherence Tomography Applications
- Atherosclerosis and Cardiovascular Diseases
- Dermatologic Treatments and Research
- Advanced Glycation End Products research
- Fibroblast Growth Factor Research
- Advanced Computing and Algorithms
Novartis (Switzerland)
2022-2024
Roche (Switzerland)
2016-2023
Howard Hughes Medical Institute
2022
Alex's Lemonade Stand Foundation
2020
University of Liverpool
2005-2017
Royal Liverpool University Hospital
2004-2016
Royal Liverpool and Broadgreen University Hospital NHS Trust
2012-2013
Warrington and Halton Teaching Hospitals NHS Foundation Trust
2006-2007
Warrington Hospital
2007
Walton Hospital
2005
PurposeThe phase 2 BOULEVARD trial compared safety and efficacy of faricimab, a novel bispecific antibody targeting angiopoietin-2 vascular endothelial growth factor-A (VEGF-A), with ranibizumab in patients diabetic macular edema (DME).DesignThe (ClinicalTrials.gov identifier, NCT02699450) was prospective, randomized, active comparator-controlled, double-masked, multicenter, study conducted at 59 sites the United States.ParticipantsThe enrolled 18 years age or older center-involving DME,...
Faricimab neutralizes angiopoietin-2 and vascular endothelial growth factor A via both simultaneous independent binding.To evaluate extended dosing with faricimab, the first bispecific antibody designed for intraocular use, in patients neovascular age-related macular degeneration.This phase 2 randomized clinical trial was a 52-week multicenter, active comparator-controlled, parallel-group study. Study participants were enrolled 25 sites US from January March 2017 treatment-naive choroidal...
Faricimab, the first bispecific antibody designed for intraocular use, simultaneously and independently binds neutralizes angiopoietin 2 (Ang-2) vascular endothelial growth factor A (VEGF-A).To assess efficacy safety of different doses regimens faricimab vs ranibizumab in patients with neovascular age-related macular degeneration (nAMD).AVENUE was a 36-week, multiple-dose-regimen, active comparator-controlled, double-masked, phase randomized clinical study performed at 58 sites United...
Voretigene neparvovec (VN) is the first available gene therapy for patients with biallelic RPE65-mediated inherited retinal dystrophy who have sufficient viable cells. PERCEIVE an ongoing, post-authorization, prospective, multicenter, registry-based observational study and largest assessing real-world, long-term safety effectiveness of VN. Here, we present outcomes 103 treated VN according to local prescribing information. The mean (SD) age was 19.5 (10.85) years, 52 (50.5%) were female,...
Background Bevacizumab (Avastin ® , Roche), which is used in cancer therapy, the ‘parent’ molecule from ranibizumab (Lucentis Novartis) was derived for treatment of neovascular age-related macular degeneration (nAMD). There were reports literature on effectiveness bevacizumab treating nAMD, but no trials. The cost per dose about 5–10% that ranibizumab. This trial a head-to-head comparison these two drugs. Objective To compare clinical and cost-effectiveness bevacizumab, regimens, nAMD....
RG7716 is a novel bispecific antibody that simultaneously binds vascular endothelial growth factor (VEGF) and another key angiogenic factor, angiopoietin 2. A phase I study of intravitreal was conducted to evaluate single-dose multiple-dose safety in patients with neovascular age-related macular degeneration (AMD).Open-label, single multiple ascending-dose study.Twenty-four diagnosed AMD best-corrected visual acuity (BCVA) 20/40 20/400 (Snellen equivalent) refractory subfoveal choroidal...
Syndromic retinitis pigmentosa (RP) is the result of several mutations expressed in rod photoreceptors, over 40 which have so far been identified. Enormous efforts are being made to relate advances unraveling patho-physiological mechanisms therapeutic approaches animal models, and eventually clinical trials on humans. This review summarizes briefly current management RP focuses new exciting treatment possibilities. To date, there no approved therapy able stop evolution or restore vision. The...
To introduce new terminology and validate its reliability for the analysis of optical coherence tomography (OCT) scans, compare clinical detection cystoid macular oedema (CMO) subretinal fluid (SRF) with OCT findings, to study effect photodynamic therapy (PDT) on foveal morphology.Patients subfoveal, predominantly classic choroidal neovascularisation (CNV) secondary age related degeneration (AMD) undergoing PDT were evaluated refraction protocol best corrected logMAR visual acuity (VA), slit...
<b>Aim:</b> To compare the visual acuity (VA), spherical equivalent refractive error, motility, and anatomical outcomes in children with treated regressed threshold stage 3 retinopathy of prematurity (ROP) those spontaneously subthreshold ROP. <b>Method:</b> 6 month year data collected from infants examined between 1989 1999 ROP, or without treatment were retrospectively reviewed. <b>Results:</b> 85 included this study. 40 eyes received cryotherapy, 81 laser photocoagulation, 34 had Grating...
Late-onset retinal degeneration (L-ORD) is a rare autosomal dominant dystrophy, characterised by extensive sub-retinal pigment epithelium (RPE) deposits, RPE atrophy, choroidal neovascularisation and photoreceptor cell death associated with severe visual loss. L-ORD shows striking phenotypic similarities to age-related macular (AMD), common genetically complex disorder, which can lead misdiagnosis in the early stages. To date, single missense mutation (S163R) C1QTNF5 gene, encoding C1q And...
Neovascular age-related macular degeneration (nAMD) shows variable treatment response to intravitreal anti-VEGF. This analysis compared the potential of different artificial intelligence (AI)-based machine learning models using OCT and clinical variables accurately predict at baseline best-corrected visual acuity (BCVA) 9 months in ranibizumab patients with nAMD.Retrospective analysis.Baseline imaging data from subfoveal choroidal neovascularization secondary dengeration.Baseline 502 study...
<h3>Aims</h3> To report the effectiveness of intravitreal ranibizumab treatment for neovascular age-related macular degeneration in a tertiary centre. <h3>Methods</h3> 1 year prospective cohort study patients with diagnosis on fundus fluorescein angiography treated ranibizumab. Patients received three consecutive monthly treatments, followed by clinician-determined re-treatment strategy. Data collected included demographic details, baseline and subsequent follow-up visit measurements,...
Purpose: To evaluate a prototype home optical coherence tomography device and automated analysis software for detection quantification of retinal fluid relative to manual human grading in cohort patients with neovascular age-related macular degeneration. Methods: Patients undergoing anti-vascular endothelial growth factor therapy were enrolled this prospective observational study. In 136 scans from 70 using the device, segmentation was performed compared gradings across all types...
Background: To evaluate the performance of a machine-learning (ML) algorithm to detect and classify choroidal neovascularization (CNV), secondary age-related macular degeneration (AMD) on spectral-domain optical coherence tomography (SD-OCT) images. Methods: Baseline fluorescein angiography (FA) SD-OCT images from 1037 treatment-naive study eyes 531 fellow eyes, without advanced AMD phase 3 HARBOR trial (NCT00891735), were used develop, train, cross-validate an ML pipeline combining...
Abstract We describe four members spanning three generations of a Caucasian family affected with distal arthrogryposis (DA). Based on Hall's original classification, we have placed our under type IIB and present previously unreported ophthalmic features. All the had different degrees ophthalmoplegia, ptosis, astigmatism, strabismus. Other findings in included keratoconus index patient, which was associated abnormal electron microscopy cornea increased thickness central cornea, small axial...
Purpose.: To evaluate changes in the multifocal electroretinogram (mfERG) patients with neovascular age-related macular degeneration (nAMD) undergoing ranibizumab treatment. Methods.: This was an observational, longitudinal, prospective study. Treatment-naive nAMD who met inclusion and exclusion criteria underwent a course of monthly injections over 3 months. At baseline month 3, each subject evaluated best corrected visual acuity (BCVA), contrast sensitivity (CS), fluorescein indocyanine...
A 26-year-old white woman presented with a 1-year history of reduced vision in both eyes, bilateral yellowish deposits the central macula, and pale yellow retinal flecks extending to midretinal periphery. Choroidal neovascularization (CNV) was confirmed her left eye. On optical coherence tomography, eyes showed diffuse intraretinal cystic spaces, thickening separation photoreceptor layer from pigment epithelium (RPE), subretinal fluid, focal at level RPE fovea. diagnosis autosomal recessive...